Literature DB >> 11265769

A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphocyte responses using instant dentritomas.

L M Holmes1, J Li, R P Sticca, T E Wagner, Y Wei.   

Abstract

The generation of fused cells between dendritic cells (DC) and tumor cells is a very effective approach for tumor antigen presentation in cancer immunotherapy. However, the application of this approach in clinical studies is limited by the need for established tumor cell lines and the time-consuming procedures for selecting and expanding the fused cells. In the current study, the authors report a rapid, novel approach to produce fused cells between DCs and primary tumor cells from patients with malignant melanoma. Peripheral blood DCs and a primary tumor cell culture were generated from the same patients, labeled with fluorescent green and red dyes, respectively, and fused. The fused cells were isolated by fluorescence-activated cell sorting. Because the fused cells do not need to be expanded, these cell hybrids have been named instant dendritomas. Fluorescence-activated cell sorting analysis showed that instant dendritomas express the key molecules for antigen presentation (HLA-A, B, C; HLA-DR; CD80; and CD86). In vitro studies have shown that instant dendritomas effectively activated autologous CD8+ T lymphocytes to proliferate and secret interferon-gamma. More importantly, the activated CD8+ T lymphocytes effectively lysed the patients' primary tumor cells. This approach represents a practical clinical strategy for cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11265769

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  5 in total

1.  Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo.

Authors:  Jin-Kun Zhang; Jun Li; Juan Zhang; Hai-Bin Chen; Su-Biao Chen
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

2.  Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.

Authors:  Maria R Parkhurst; Cormac DePan; John P Riley; Steven A Rosenberg; Suyu Shu
Journal:  J Immunol       Date:  2003-05-15       Impact factor: 5.422

3.  Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses.

Authors:  Andreas Lundqvist; Andreas Palmborg; Gawa Bidla; Mike Whelan; Hardev Pandha; Pavel Pisa
Journal:  Med Oncol       Date:  2004       Impact factor: 3.064

Review 4.  Novel dendritic cell-based vaccination in late stage melanoma.

Authors:  Erika J Schneble; Xianzhong Yu; T E Wagner; George E Peoples
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Purified dendritic cell-tumor fusion hybrids supplemented with non-adherent dendritic cells fraction are superior activators of antitumor immunity.

Authors:  Yunfei Zhang; Wen Luo; Yucai Wang; Yunyan Liu; Lianhe Zheng
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.